In male NSG mice bearing subcutaneous MHCCLM3 xenografts, Fostamatinib disodium treatment yielded average tumor weights of 1.8 g versus 3.2 g with vehicle after 28 days; the difference was not statistically significant (p = 0.1031). In Apoe−/− mice, dietary Fostamatinib disodium at 0.3 % prevented the rise in circulating Ly6Chigh monocytes associated with hypercholesterolemia and atherogenesis after 8 weeks of HCD. Peripheral monocyte numbers remained unaffected with or without fostamatinib for 4 days. [2,3]
Tumor weights in a subcutaneous xenograft model
Animal study · Male NSG (NOD scid gamma) mice; subcutaneous xenograft model of MHCCLM3 cells [2]
Male NSG (NOD scid gamma) mice bearing subcutaneous MHCCLM3 xenografts received Fostamatinib disodium at 80 mg/kg daily by oral gavage. After 28 days of treatment, average tumor weights were 3.2 g with vehicle and 1.8 g with fostamatinib; the difference was not statistically significant (p = 0.1031).
Conditions shared by the study groups
- Route
- oral gavage
- Treatment course
- daily; 28 days of treatment
- Vehicle
- 30% PEG 400, 5% PPG and 0.5% Tween 80
- Fostamatinib disodium 80 mg/kg
- Model: Male NSG (NOD scid gamma) mice; subcutaneous xenograft model of MHCCLM3 cells
Methods and source locations
Compound reported in the paper: Fostamatinib disodium; Compound label in the paper: Fostamatinib
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
2. Results > 2.2. Drug Repurposing Predictions to Reverse Sorafenib Resistance in HCC > 2.2.4. Characterization of Fostamatinib as Anti-HCC Drug (S70, S73, S74); 4. Materials and Methods > 4.5. Mouse Strains, Animal Husbandry and Treatment (S110, S114, S115, S117); Figure 5 legend (S195)
tumor weights at the end of the treatment: tumor weights at the end of the treatment; comparator: vehicle (30% PEG 400, 5% PPG and 0.5% Tween 80) — 2. Results > 2.2. Drug Repurposing Predictions to Reverse Sorafenib Resistance in HCC > 2.2.4. Characterization of Fostamatinib as Anti-HCC Drug (S73, S74); 4. Materials and Methods > 4.5. Mouse Strains, Animal Husbandry and Treatment (S115); Figure 5 legend (S195)
Fostamatinib disodium 80 mg/kg · 2. Results > 2.2. Drug Repurposing Predictions to Reverse Sorafenib Resistance in HCC > 2.2.4. Characterization of Fostamatinib as Anti-HCC Drug (S73, S74); 4. Materials and Methods > 4.5. Mouse Strains, Animal Husbandry and Treatment (S115, S117)
Circulating monocytes in Apoe−/− mice
Animal study · Apoe−/− mice (n = 14 per group) [3]
After 8 weeks of HCD, fostamatinib prevented the rise in circulating Ly6Chigh monocytes associated with hypercholesterolemia and atherogenesis.
Conditions shared by the study groups
- Route
- incorporated at 0.3 % (w/w) into the diet
- Treatment course
- after 8 weeks of HCD
- Vehicle
- without carrier
- Fostamatinib disodium 0.3 %
- Model: Apoe−/− mice (n = 14 per group)
Methods and source locations
Compound reported in the paper: Fostamatinib disodium; Compound label in the paper: Fostamatinib
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Methods > Animal models (S1, S2); Results > SYK inhibition attenuates atherosclerotic plaque development in Apoe−/− mice (S30); Results > SYK inhibition reduces medullary and extramedullary myelopoiesis in atherosclerotic Apoe−/− mice (S37, S43, S45, S51)
Identification and quantification of blood monocyte subsets by flow cytometry: Identification and quantification of blood monocyte subsets by flow cytometry; comparator: control (gray) — Results > SYK inhibition reduces medullary and extramedullary myelopoiesis in atherosclerotic Apoe−/− mice (S37, S43, S51)
Fostamatinib disodium 0.3 % · Methods > Animal models (S2); Results > SYK inhibition reduces medullary and extramedullary myelopoiesis in atherosclerotic Apoe−/− mice (S37, S43, S51)
